Alkem Laboratories shines on launching Favipiravir for COVID-19 treatment

06 Aug 2020 Evaluate

Alkem Laboratories is currently trading at Rs. 2955.00, up by 113.00 points or 3.98% from its previous closing of Rs. 2842.00 on the BSE.

The scrip opened at Rs. 2900.00 and has touched a high and low of Rs. 2972.60 and Rs. 2900.00 respectively. So far 4295 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2975.65 on 04-Aug-2020 and a 52 week low of Rs. 1,682.10 on 07-Aug-2019.

Last one week high and low of the scrip stood at Rs. 2975.65 and Rs. 2538.20 respectively. The current market cap of the company is Rs. 33980.37 crore.

The promoters holding in the company stood at 62.43%, while Institutions and Non-Institutions held 15.52% and 21.80% respectively.

Alkem Laboratories has launched Favipiravir under the brand name ‘Alfluenza’ in India for the management of mild to moderate cases of COVID-19. Favipiravir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Alkem Laboratories Share Price

4821.20 -130.70 (-2.64%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.